Case Study

Sanofi-Aventis has acquired Zentiva N.V.

Sanofi-Aventis has successfully completed and settled the voluntary tender offer for all of Zentiva N.V.'s shares. Total value of this transaction is over US$2 billion.

Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops and distributes a broad offering of medicines, vaccines and integrated healthcare solutions adapted to local needs and means. Sanofi-Aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Zentiva N.V. is an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products. The company has leading positions in the pharmaceutical markets in the Czech Republic, Slovakia, Romania and Turkey, and is growing rapidly in Poland, Russia, Bulgaria, Hungary, the Ukraine and the Baltic States.

Oaklins' team in the Czech Republic acted as the tender agent to Sanofi-Aventis in relation to the voluntary tender offer for all of Zentiva N.V.'s shares. From July 2008 to March 2009, the Czech team arranged the purchase of approximately 70% of the issued share capital of Zentiva.

Tombstone image for Sanofi-Aventis has acquired Zentiva N.V.

KEY DEAL CONTACTS

David Tajzich

Czech Republic

Managing Director

VIEW PROFILE